Amedisys to Host Conference Call Today at 10:00 a.m. ET
BATON ROUGE, La.--(BUSINESS WIRE)--
Amedisys, Inc. (NASDAQ: AMED), a leading home health and hospice
company, today reported its financial results for the first quarter
ended March 31, 2013.
Three-Month Periods Ended March 31, 2013 and 2012
After adding back $2.0 million and $3.7 million ($1.2 million and $2.2
million, net of tax) or $0.04 and $0.07 per diluted share for legal fees
associated with investigations, the following would have been our
adjusted results:*
-
Net service revenue of $339.2 million compared to $370.8 million in
2012, a decrease of 8.5%.
-
Net income from continuing operations attributable to Amedisys, Inc.,
of $3.9 million compared to $8.6 million in 2012, a decrease of 54.8%.
-
Net income from continuing operations attributable to Amedisys, Inc.
per diluted share of $0.13 compared to $0.29 per diluted share in
2012, a decrease of 55.2%.
-
Earnings before interest, taxes, depreciation and amortization
attributable to continuing operations (“EBITDA”) of $17.3 million
compared to $26.9 million in 2012, a decrease of 35.8%.
William F. Borne, Chief Executive Officer stated, “Results for the first
quarter were impacted by declining volumes and sequestration, but
slightly offset by year-over-year increases in admissions and cost
control efforts. Clearly, despite encouraging trends, quarterly
performance did not meet our expectations. Consequently, we are
implementing plans to consolidate or divest non-performing care centers,
trim our corporate infrastructure and refine our patient care management
strategy focused on delivering the optimal level of care to drive
improved clinical outcomes for our patients. We believe these
initiatives, along with a strong focus on volume growth and continued
cost control efforts, will position Amedisys to capitalize on the
changing healthcare landscape and continue to provide the best care for
our patients in the lowest cost setting.”
2013 Guidance
-
Net service revenue is anticipated to be in the range of $1.280
billion to $1.320 billion.
-
Diluted earnings per share is expected to be in the range of $0.45 to
$0.55 based on an estimated 31.5 million shares outstanding.
This guidance excludes any one-time costs associated with our announced
market exit activity or corporate expense initiatives. Our guidance
includes an estimate of legal costs associated with our on-going
government investigations.
We urge caution in considering the current trends and 2013 guidance
disclosed in this press release. The home health and hospice industry is
highly competitive and subject to intensive regulations, and trends and
guidance are subject to numerous factors, risks, and uncertainties, some
of which are referenced in the cautionary language below and others that
are described more fully in our reports filed with the Securities and
Exchange Commission (“SEC”) including our Annual Report on Form 10-K for
the fiscal year ended December 31, 2012, and subsequent Quarterly
Reports on Form 10-Q, and current reports on Form 8-K which can be found
on the SEC’s internet website, http://www.sec.gov,
and our internet website, http://www.amedisys.com.
We disclaim any obligations to update disclosed information on trends.
* See page 7 for the reconciliations of non-GAAP financial measures
Earnings Call and Webcast Information
To participate in the conference call, please call a few minutes before
10:00 a.m. ET on Tuesday, April 30, 2013, to either (877) 512-9171 (Toll
free) or (815) 573-0979 (Toll), use conference ID #35067959. A replay of
the conference call will be available through May 7, 2013. The replay
dial in number is (855) 859-2056 (Toll free) or (404) 537-3406 (Toll),
use conference ID #35067959.
The call will also be available through our website and for seven days
thereafter at the following web address: http://investors.amedisys.com.
We are headquartered in Baton Rouge, Louisiana. Our common stock trades
on the NASDAQ Global Select Market under the symbol “AMED.”
Additional information
Our company website address is www.amedisys.com.
We use our website as a channel of distribution for important company
information. Important information, including press releases, analyst
presentations and financial information regarding our company, is
routinely posted on and accessible on the Investor Relations subpage of
our website, which is accessible by clicking on the tab labeled
“Investors” on our website home page. We also use our website to
expedite public access to time-critical information regarding our
company in advance of or in lieu of distributing a press release or a
filing with the SEC disclosing the same information. Therefore,
investors should look to the Investor Relations subpage of our website
for important and time-critical information. Visitors to our website can
also register to receive automatic e-mail and other notifications
alerting them when new information is made available on the Investor
Relations subpage of our website.
Forward-Looking Statements
When included in this press release, words like “believes,” “belief,”
“expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,”
“may,” “might,” “would,” “should” and similar expressions are intended
to identify forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements involve a variety of risks and uncertainties that could cause
actual results to differ materially from those described therein. These
risks and uncertainties include, but are not limited to the following:
changes in Medicare and other medical payment levels, our ability to
open care centers, acquire additional care centers and integrate and
operate these care centers effectively, changes in or our failure to
comply with existing Federal and State laws or regulations or the
inability to comply with new government regulations on a timely basis,
competition in the home health industry, changes in the case mix of
patients and payment methodologies, changes in estimates and judgments
associated with critical accounting policies, our ability to maintain or
establish new patient referral sources, our ability to attract and
retain qualified personnel, changes in payments and covered services due
to the economic downturn and deficit spending by Federal and State
governments, future cost containment initiatives undertaken by
third-party payors, our access to financing due to the volatility and
disruption of the capital and credit markets, our ability to meet debt
service requirements and comply with covenants in debt agreements,
business disruptions due to natural disasters or acts of terrorism, our
ability to integrate and manage our information systems, changes in or
developments with respect to any litigation or investigations relating
to the Company, including the SEC investigation and the U.S. Department
of Justice Civil Investigative Demand and various other matters, many of
which are beyond our control.
Because forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified, you
should not rely on any forward-looking statement as a prediction of
future events. We expressly disclaim any obligation or undertaking and
we do not intend to release publicly any updates or changes in our
expectations concerning the forward-looking statements or any changes in
events, conditions or circumstances upon which any forward-looking
statement may be based, except as required by law.
Non-GAAP Financial Measures
This press release includes the following non-GAAP financial measures as
defined under SEC rules: EBITDA, defined as net income from continuing
operations attributable to Amedisys, Inc. before provision for income
taxes, net interest expense and depreciation and amortization, adjusted
EBITDA, defined as EBITDA plus legal fees associated with
investigations, adjusted net income from continuing operations
attributable to Amedisys, Inc., defined as net income from continuing
operations attributable to Amedisys, Inc. plus legal fees associated
with investigations, and adjusted net income from continuing operations
attributable to Amedisys, Inc. per diluted share, defined as net income
from continuing operations attributable to Amedisys, Inc. common
stockholders per diluted share plus the earnings per share effect of
legal fees associated with investigations. In accordance with SEC rules,
we have provided herein a reconciliation of these non-GAAP financial
measures to the most directly comparable measures under GAAP. Management
believes that these are useful gauges of our performance and are common
measures used in our industry to assess relative financial performance
among companies.
|
|
| |
|
| |
AMEDISYS, INC. AND SUBSIDIARIES SELECT CONSOLIDATED FINANCIAL STATEMENT DATA AND SUPPLEMENTAL
INFORMATION (Amounts in thousands, except share, per share data and
statistical information) (Unaudited) |
| | | | | |
|
Balance Sheet Information | | | | | | |
| | | | | |
|
| | | | | |
|
| | | March 31, 2013 | | | December 31, 2012 |
| ASSETS | | | | | | |
|
Current assets:
| | | | | | |
|
Cash and cash equivalents
| | |
$
|
7,021
| | | |
$
|
14,545
| |
|
Patient accounts receivable, net of allowance for doubtful accounts
of $18,991 and $20,994 | | | |
144,659
| | | | |
169,172
| |
|
Prepaid expenses
| | | |
14,478
| | | | |
10,631
| |
|
Other current assets
| | |
|
16,229
|
| | |
|
11,440
|
|
|
Total current assets
| | | |
182,387
| | | | |
205,788
| |
|
Property and equipment, net of accumulated depreciation of $118,280,
and $113,154 | | | |
156,481
| | | | |
156,709
| |
|
Goodwill
| | | |
209,994
| | | | |
209,594
| |
|
Intangible assets, net of accumulated amortization of $24,119 and
$23,457 | | | |
46,792
| | | | |
47,050
| |
|
Deferred tax asset
| | | |
91,808
| | | | |
92,804
| |
|
Other assets, net
| | |
|
24,855
|
| | |
|
18,650
|
|
|
Total assets
| | |
$
|
712,317
|
| | |
$
|
730,595
|
|
| | | | | |
|
| LIABILITIES AND EQUITY | | | | | | |
|
Current Liabilities:
| | | | | | |
|
Accounts payable
| | |
$
|
27,646
| | | |
$
|
29,175
| |
|
Payroll and employee benefits
| | | |
78,919
| | | | |
79,341
| |
|
Accrued expenses
| | | |
57,054
| | | | |
54,855
| |
|
Current portion of long-term obligations
| | | |
35,807
| | | | |
35,807
| |
|
Current portion of deferred income taxes
| | |
|
3,395
|
| | |
|
5,609
|
|
|
Total current liabilities
| | | |
202,821
| | | | |
204,787
| |
|
Long-term obligations, less current portion
| | | |
42,952
| | | | |
66,904
| |
|
Other long-term obligations
| | |
|
4,761
|
| | |
|
4,671
|
|
|
Total liabilities
| | |
|
250,534
|
| | |
|
276,362
|
|
| | | | | |
|
|
Equity:
| | | | | | |
|
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none
issued or outstanding
| | | |
—
| | | | |
—
| |
|
Common stock, $0.001 par value, 60,000,000 shares authorized;
32,173,099 and 31,876,508 shares issued; and 31,382,932 and
31,086,619 shares outstanding
| | | |
32
| | | | |
32
| |
|
Additional paid-in capital
| | | |
456,046
| | | | |
450,792
| |
|
Treasury stock at cost, 790,167 and 789,889 shares of common stock
| | | |
(17,119
|
)
| | | |
(17,116
|
)
|
|
Accumulated other comprehensive income
| | | |
15
| | | | |
15
| |
|
Retained earnings
| | |
|
21,296
|
| | |
|
18,617
|
|
|
Total Amedisys, Inc. stockholders’ equity
| | | |
460,270
| | | | |
452,340
| |
|
Noncontrolling interests
| | |
|
1,513
|
| | |
|
1,893
|
|
|
Total equity
| | |
|
461,783
|
| | |
|
454,233
|
|
|
Total liabilities and equity
| | |
$
|
712,317
|
| | |
$
|
730,595
|
|
|
|
| |
|
| |
Income Statement Information | | | | | | |
| | | | | |
|
| | | For the Three-Month Periods Ended March 31, |
| | | 2013 | | | 2012 |
|
Net service revenue
| | |
$
|
339,175
| | | |
$
|
370,833
| |
|
Cost of service, excluding depreciation and amortization
| | | |
192,504
| | | | |
208,506
| |
|
General and administrative expenses:
| | | | | | |
|
Salaries and benefits
| | | |
82,794
| | | | |
87,077
| |
|
Non-cash compensation
| | | |
2,056
| | | | |
2,482
| |
|
Other
| | | |
43,562
| | | | |
44,394
| |
|
Provision for doubtful accounts
| | | |
3,967
| | | | |
5,863
| |
|
Depreciation and amortization
| | |
|
10,123
|
| | |
|
10,054
|
|
|
Operating expenses
| | |
|
335,006
|
| | |
|
358,376
|
|
|
Operating income
| | | |
4,169
| | | | |
12,457
| |
|
Other (expense) income:
| | | | | | |
|
Interest income
| | | |
11
| | | | |
15
| |
|
Interest expense
| | | |
(1,106
|
)
| | | |
(2,074
|
)
|
|
Equity in earnings from equity investments
| | | |
363
| | | | |
305
| |
|
Miscellaneous, net
| | |
|
59
|
| | |
|
429
|
|
|
Total other expense, net
| | |
|
(673
|
)
| | |
|
(1,325
|
)
|
|
Income before income taxes
| | | |
3,496
| | | | |
11,132
| |
|
Income tax expense
| | |
|
(1,363
|
)
| | |
|
(4,620
|
)
|
|
Income from continuing operations
| | | |
2,133
| | | | |
6,512
| |
|
Discontinued operations, net of tax
| | |
|
—
|
| | |
|
(1,049
|
)
|
|
Net income
| | | |
2,133
| | | | |
5,463
| |
|
Net loss (income) attributable to noncontrolling interests
| | |
|
546
|
| | |
|
(43
|
)
|
|
Net income attributable to Amedisys, Inc. | | |
$
|
2,679
|
| | |
$
|
5,420
|
|
|
Basic earnings per common share:
| | | | | | |
|
Income from continuing operations attributable to Amedisys, Inc.
common stockholders
| | |
$
|
0.09
| | | |
$
|
0.22
| |
|
Discontinued operations, net of tax
| | |
|
—
|
| | |
|
(0.04
|
)
|
|
Net income attributable to Amedisys, Inc. common stockholders
| | |
$
|
0.09
|
| | |
$
|
0.18
|
|
|
Weighted average shares outstanding
| | |
|
30,640
|
| | |
|
29,389
|
|
|
Diluted earnings per common share:
| | | | | | |
|
Income from continuing operations attributable to Amedisys, Inc.
common stockholders
| | |
$
|
0.09
| | | |
$
|
0.22
| |
|
Discontinued operations, net of tax
| | |
|
—
|
| | |
|
(0.04
|
)
|
|
Net income attributable to Amedisys, Inc. common stockholders
| | |
$
|
0.09
|
| | |
$
|
0.18
|
|
|
Weighted average shares outstanding
| | |
|
31,104
|
| | |
|
29,780
|
|
|
Amounts attributable to Amedisys, Inc. common stockholders:
| | | | | | |
|
Income from continuing operations
| | |
$
|
2,679
| | | |
$
|
6,469
| |
|
Discontinued operations, net of tax
| | |
|
—
|
| | |
|
(1,049
|
)
|
|
Net income
| | |
$
|
2,679
|
| | |
$
|
5,420
|
|
|
|
| |
|
| |
Cash Flow Information | | | | | | |
| | | | | |
|
| | | For the Three-Month Periods Ended March 31, |
| | | 2013 | | | 2012 |
|
Net cash provided by operating activities
| | |
$
|
32,416
| | | |
$
|
10,927
| |
|
Net cash used in investing activities
| | | |
(16,825
|
)
| | | |
(10,053
|
)
|
|
Net cash used in financing activities
| | |
|
(23,115
|
)
| | |
|
(7,588
|
)
|
|
Net decrease in cash and cash equivalents
| | | |
(7,524
|
)
| | | |
(6,714
|
)
|
|
Cash and cash equivalents at beginning of period
| | |
|
14,545
|
| | |
|
48,004
|
|
|
Cash and cash equivalents at end of period
| | |
$
|
7,021
|
| | |
$
|
41,290
|
|
|
|
| |
|
| |
Supplemental Information—Home Health |
| | | | | |
|
| | | For the Three-Month Periods Ended March 31, |
| | | 2013 | | | 2012 |
| Financial Information (in millions): | | | | | | |
| Medicare | | |
$
|
221.1
| | | |
$
|
242.4
| |
|
Non-Medicare | | |
|
51.2
|
| | |
|
59.0
|
|
|
Net service revenue
| | | |
272.3
| | | | |
301.4
| |
|
Cost of service
| | |
|
157.1
|
| | |
|
172.0
|
|
|
Gross margin
| | | |
115.2
| | | | |
129.4
| |
|
Other operating expenses
| | |
|
89.7
|
| | |
|
97.8
|
|
| | | | | |
|
|
Operating income
| | |
$
|
25.5
|
| | |
$
|
31.6
|
|
| | | | | |
|
| Key Statistical Data: | | | | | | |
| Medicare: | | | | | | |
| Same Store Volume (1): | | | | | | |
|
Revenue
| | | |
(8
|
)%
| | | |
(8
|
)%
|
|
Admissions
| | | |
2
|
%
| | | |
(2
|
)%
|
|
Recertifications
| | | |
(17
|
)%
| | | |
(5
|
)%
|
| Total: | | | | | | |
|
Admissions
| | | |
52,122
| | | | |
51,153
| |
|
Recertifications
| | | |
29,698
| | | | |
35,794
| |
|
Completed Episodes
| | | |
78,816
| | | | |
82,204
| |
|
Visits
| | | |
1,422,332
| | | | |
1,625,473
| |
|
Average revenue per completed episode (2)
| | | $ |
2,782
| | | | $ |
2,882
| |
|
Visits per completed episode (3)
| | | |
17.4
| | | | |
18.6
| |
| Non-Medicare: | | | | | | |
|
Admissions
| | | |
22,423
| | | | |
23,192
| |
|
Recertifications
| | | |
8,407
| | | | |
9,731
| |
|
Visits
| | | |
436,035
| | | | |
504,398
| |
| Total: | | | | | | |
|
Cost per Visit
| | | $ |
84.53
| | | | $ |
80.76
| |
|
Visits
| | | |
1,858,367
| | | | |
2,129,871
| |
|
(1)
|
| Medicare revenue, admissions or recertifications growth is the
percent increase (decrease) in our Medicare revenue, admissions or
recertifications for the period as a percent of the Medicare
revenue, admissions or recertifications of the prior period.
|
|
(2)
| |
Average Medicare revenue per completed episode is the average
Medicare revenue earned for each Medicare completed episode of care.
|
|
(3)
| | Medicare visits per completed episode are the home health Medicare
visits on completed episodes divided by the home health Medicare
episodes completed during the period.
|
|
|
| |
|
| |
Supplemental Information—Hospice |
| | | | | |
|
| | | For the Three-Month Periods Ended March 31, |
| | | 2013 | | | 2012 |
| Financial Information (in millions): | | | | | | |
| Medicare | | |
$
|
63.0
| | | |
$
|
65.3
| |
|
Non-Medicare | | |
|
3.9
|
| | |
|
4.1
|
|
|
Net service revenue
| | | |
66.9
| | | | |
69.4
| |
|
Cost of service
| | |
|
35.4
|
| | |
|
36.5
|
|
|
Gross margin
| | | |
31.5
| | | | |
32.9
| |
|
Other operating expenses
| | |
|
19.8
|
| | |
|
17.7
|
|
|
Operating income
| | |
$
|
11.7
|
| | |
$
|
15.2
|
|
| Key Statistical Data: | | | | | | |
|
Same store Medicare revenue growth (1)
| | | |
(5
|
)%
| | | |
17
|
%
|
|
Hospice admits
| | | |
4,992
| | | | |
4,902
| |
|
Average daily census
| | | |
5,091
| | | | |
5,190
| |
|
Revenue per day
| | |
$
|
146.07
| | | |
$
|
147.07
| |
|
Cost of service per day
| | |
$
|
77.10
| | | |
$
|
77.10
| |
|
Average length of stay
| | | |
103
| | | | |
91
| |
|
(1)
|
|
Same store Medicare revenue growth is the percent increase in our
Medicare revenue for the period as a percent of the Medicare revenue
of the prior period.
|
AMEDISYS, INC. AND SUBSIDIARIES |
SELECT CONSOLIDATED KEY STATISTICAL DATA AND |
RECONCILIATION OF NON-GAAP FINANCIAL MEASURE TO GAAP FINANCIAL
STATEMENTS |
(Amounts in thousands, except key statistical and per share
data) |
(Unaudited) |
|
|
| |
|
| |
| | | | | |
|
| | | For the Three-Month Periods Ended March 31, |
| | | 2013 | | | 2012 |
| Key Statistical Data: | | | | | | |
| General | | | | | | |
|
Number of home health care centers
| | |
427
| | |
437
|
|
Number of hospice care centers
| | |
97
| | |
88
|
|
Number of care centers acquired (1)
| | |
1
| | |
—
|
|
Number of care centers opened as start-up locations (1)
| | |
—
| | |
2
|
|
Days revenue outstanding, net (2)
| | |
37.2
| | |
38.4
|
|
(1)
|
|
Includes both home health and hospice care centers.
|
|
(2)
| |
Our calculation of days revenue outstanding, net at March 31, 2013
and 2012 is derived by dividing our ending patient accounts
receivable (i.e., net of estimated revenue adjustments and allowance
for doubtful accounts) by our average daily net patient revenue for
the three month-period ended March 31, 2013 and 2012, respectively.
|
|
|
| |
|
| |
Earnings From Continuing Operations Before Interest, Taxes,
Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA: |
| | | | | |
|
| | | For the Three-Month Periods Ended March 31, |
| | | 2013 | | | 2012 |
|
Net income from continuing operations attributable to Amedisys, Inc. | | |
$
|
2,679
| | |
$
|
6,469
|
|
Add:
| | | | | | |
|
Provision for income taxes
| | | |
1,363
| | | |
4,620
|
|
Interest expense, net
| | | |
1,095
| | | |
2,059
|
|
Depreciation and amortization
| | |
|
10,123
| | |
|
10,054
|
|
EBITDA (1)
| | |
$
|
15,260
| | |
$
|
23,202
|
|
Add:
| | | | | | |
|
Legal fees (investigations)
| | |
|
2,003
| | |
|
3,707
|
|
Adjusted EBITDA (2)
| | |
$
|
17,263
| | |
$
|
26,909
|
|
|
Adjusted Net Income From Continuing Operations Attributable
to Amedisys, Inc.: |
|
|
| |
|
| |
| | | For the Three-Month Periods Ended March 31, |
| | | 2013 | | | 2012 |
|
Net income from continuing operations attributable to Amedisys, Inc. | | |
$
|
2,679
| | |
$
|
6,469
|
|
Add:
| | | | | | |
|
Legal fees (investigations)
| | |
|
1,222
| | |
|
2,169
|
|
Adjusted net income from continuing operations attributable to
Amedisys, Inc. (3)
| | |
$
|
3,901
| | |
$
|
8,638
|
|
|
| |
|
| |
Adjusted Net Income From Continuing Operations Attributable
to Amedisys, Inc. per Diluted Share: |
| | | | | |
|
| | | For the Three-Month Periods Ended March 31, |
| | | 2013 | | | 2012 |
|
Net income from continuing operations attributable to Amedisys, Inc.
common stockholders per diluted share
| | |
$
|
0.09
| | |
$
|
0.22
|
|
Add:
| | | | | | |
|
Legal fees (investigations)
| | |
|
0.04
| | |
|
0.07
|
|
Adjusted net income from continuing operations attributable to
Amedisys, Inc. common stockholders per diluted share (4)
| | |
$
|
0.13
| | |
$
|
0.29
|
|
(1)
|
|
EBITDA is defined as net income from continuing operations
attributable to Amedisys, Inc. before provision for income taxes,
net interest expense, and depreciation and amortization. EBITDA
should not be considered as an alternative to, or more meaningful
than, income before income taxes, cash flow from operating
activities, or other traditional indicators of operating
performance. This calculation of EBITDA may not be comparable to a
similarly titled measure reported by other companies, since not all
companies calculate this non-GAAP financial measure in the same
manner.
|
|
(2)
| |
Adjusted EBITDA is defined as net income from continuing operations
attributable to Amedisys, Inc. before provision for income taxes,
net interest expense, depreciation and amortization plus legal fees
associated with investigations. Adjusted EBITDA should not be
considered as an alternative to, or more meaningful than, income
before income taxes, cash flow from operating activities, or other
traditional indicators of operating performance. This calculation of
adjusted EBITDA may not be comparable to a similarly titled measure
reported by other companies, since not all companies calculate this
non-GAAP financial measure in the same manner.
|
|
(3)
| |
Adjusted net income from continuing operations attributable to
Amedisys, Inc. is defined as net income from continuing operations
attributable to Amedisys, Inc. plus legal fees associated with
investigations. Adjusted net income from continuing operations
attributable to Amedisys, Inc. should not be considered as an
alternative to, or more meaningful than, income before income taxes,
cash flow from operating activities, or other traditional indicators
of operating performance. This calculation of adjusted net income
from continuing operations attributable to Amedisys, Inc. may not be
comparable to a similarly titled measure reported by other
companies, since not all companies calculate this non-GAAP measure
in the same manner.
|
|
(4)
| |
Adjusted net income from continuing operations attributable to
Amedisys, Inc. common stockholders per diluted share is defined as
diluted earnings from continuing operations per share plus the
earnings per share effect of legal fees associated with
investigations. Adjusted net income from continuing operations
attributable to Amedisys, Inc. common stockholders per diluted share
should not be considered as an alternative to, or more meaningful
than, income before income taxes, cash flow from operating
activities, or other traditional indicators or operating
performance. This calculation of adjusted net income from continuing
operations attributable to Amedisys, Inc. common stockholders per
diluted share may not be comparable to a similarly titled measure
reported by other companies, since not all companies calculate this
non-GAAP financial measure in the same manner.
|
Amedisys, Inc.
Investor Contact:
Tom
Dolan, 225-299-3391
Senior Vice President, Finance and
Treasurer
[email protected]
or
Media
Contact:
Kendra Kimmons, 225-299-3720
Director
of Communications
[email protected]
Source: Amedisys, Inc.